REGN241122C795000
- 0.42
- -0.98-70.00%
Regeneron Pharmaceuticals Newsroom
Regeneron Pharmaceuticals's Options: A Look at What the Big Money Is Thinking
Tuesday Market Falls, SMCI Flies, Big Box Retail Reports Mixed | Live Stock
Here's Why Regeneron Pharmaceuticals (REGN) Declined in Q3
Monday Market Slow but Steady, Trump Buying Crypto Firm | Wall Street Today
FDA Accepts SNY and REGN's Dupixent Re-Submitted SBLA for Urticaria
Monday Opens to S&P 500 Climb, Dow Slides as Eyes Look Toward Nvidia | Live Stock
Peering Into Regeneron Pharmaceuticals's Recent Short Interest
Express News | Regeneron Pharmaceuticals : Deutsche Bank Cuts Target Price to $805 From $900
Weekly Buzz: Not All Parties Last Forever
Market Falls to End All-Time High Week | Wall Street Today
Express News | CNBC Halftime Report Final Trades: Berkshire Hathaway Inc. - B Shares, Regeneron Pharmaceuticals, DocuSign, Leidos Holdings
Market Falls Friday After Light Earnings and 13F's | Live Stock
Check Out What Whales Are Doing With REGN
FDA To Revisit Regeneron/Sanofi's Dupixent For Rare Skin Disease
Regeneron, Sanofi Say Resubmitted Application to Expand Dupixent Label Accepted in U.S.
Regeneron, Sanofi Get New FDA Review of Dupixent for CSU
Regeneron Pharmaceuticals, Sanofi Say FDA Accepts Application for Skin Disease Treatment
Express News | Sanofi - Resubmission Includes New Pivotal Data Which Confirm Dupixent Significantly Reduced Itch and Hive Activity
Express News | Dupixent® (Dupilumab) Sbla Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (Csu)
Market Falls Thursday, Powell Said Fed Will Take Things Slow | Wall Street Today